ArticleJournal of hepatocellular carcinoma2025
Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design and Validation of a Predictive Model for Hepatocellular Carcinoma Based on Genes With Differential Expression Driven by DNA Methylation.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the impact of hepatitis B virus (HBV) DNA on the efficacy of triple therapy [transarterial chemoembolization (TACE), lenvatinib, and programmed cell death protein-1 (PD-1) inhibitors] in the treatment of HBV-related unresectable hepatocellular carcinoma (u-HCC). Methods: We retrospectively collected clinical data on triple therapy for HBV-related u-HCC from January 2020 to January 2024 at Xiangyang Central Hospital. Patients with HBV-DNA ≤ 1000 IU/mL were designated the low HBV-DNA level group, and patients with HBV-DNA > 1000 IU/mL were designated the high HBV-DNA level group. The primary endpoint of this study was to compare the progression-free survival (PFS) and overall survival (OS), between the low HBV-DNA level and high HBV-DNA level groups. The secondary endpoint compares the objective response rate (ORR) between the two groups. Results: Data from 95 patients were obtained, with 41 patients in the low HBV-DNA level group and 54 patients in the high HBV-DNA level group. After treatment, the median PFS and OS was 10.00 months and 25.03 months in the low HBV-DNA level group and 7.23 months and 15.00 months in the high HBV-DNA level group (all P < 0.05). The low HBV-DNA level group had an ORR of 30 patients, and the high HBV-DNA level group had 32 patients (85.37% vs 64.81%, P = 0.024). Conclusion: HBV-DNA > 1000 IU/mL is associated with poorer prognosis in patients with HBV-related u-HCC treated with triple therapy. In triple therapy for HBV-related u-HCC, HBV-DNA levels above 1000 IU/mL should be actively controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.